Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1405&sort=end_date
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=end_date", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1419&sort=end_date", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1406&sort=end_date", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1404&sort=end_date" }, "data": [ { "type": "Grant", "id": "15763", "attributes": { "award_id": "1RF1NS138437-01A1", "title": "Impact of SARS-CoV-2 on the cerebrovasculature as a risk factor for VCID: Role of Wnt/beta-catenin", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 32579, "first_name": "WILLIAM PATRICK", "last_name": "DALEY", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-11", "end_date": "2029-07-31", "award_amount": 2549080, "principal_investigator": { "id": 31999, "first_name": "Sarah Elizabeth", "last_name": "Lutz", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2631, "ror": "", "name": "UNIVERSITY OF ILLINOIS AT CHICAGO", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "COVID-19 increases the risk of vascular contributions to cognitive impairment and dementia (VCID). VCID is one of the most prevalent forms of dementia, so the potential public health impact of the COVID-19 pandemic on future VCID is substantial. However, the mechanisms by which COVID-19 modifies VCID are unknown. Identifying mechanisms that regulate how prior COVID-19 influences the brain endothelial cell response to vascular stress is important. Here, we provide preliminary evidence that COVID-19 decreases resistance to VCID by weakening the blood-brain barrier (BBB). This is accompanied by cerebrovascular inflammation. This grant will test the novel mechanism that SARS-CoV-2 infection accelerates VCID by suppressing cerebrovascular Wnt/β-catenin signaling. In Aim 1, we determine how prior SARS-CoV-2 infection influences BBB permeability and cognition upon subsequent vascular insult, by genetic and epigenetic modification. In Aim 2 we use endothelial-targeted genetic interventions to assess the contribution of Wnt/β- cat targets to resistance to post-infectious VCID. In Aim 3, we ask whether established post-infectious VCID can be reversed by increasing cerebrovascular Wnt/β-catenin. These studies could lead to novel approaches to identify individuals at high risk for VCID and novel potential therapeutic strategies to mitigate the impact of prior infection on the development of dementia.", "keywords": [ "2019-nCoV", "ATAC-seq", "Acceleration", "Acute", "Blood - brain barrier anatomy", "Blood Vessels", "Blood brain barrier dysfunction", "COVID-19", "COVID-19 pandemic effects", "Cells", "Cerebrovascular system", "Clinic", "Cognition", "Critical Pathways", "Data", "Dementia", "Development", "Endothelial Cells", "Endothelium", "Engineering", "Epigenetic Process", "Extravasation", "Functional disorder", "Future", "Genes", "Genetic", "Goals", "Grant", "High Fat Diet", "Human", "Hypertension", "Impaired cognition", "Individual", "Infection", "Inflammation", "Inflammatory", "Knowledge", "Ligands", "Modification", "Mus", "Pathogenicity", "Pathway interactions", "Pattern", "Pericytes", "Permeability", "Phenotype", "Prevention", "Public Health", "Recording of previous events", "Recovery", "Research", "Resistance", "Respiratory Tract Infections", "Risk", "Risk Factors", "Role", "SARS-CoV-2 infection", "Signal Transduction", "Testing", "Therapeutic", "Translating", "Vascular Dementia", "Viral", "beta catenin", "blood-brain barrier permeabilization", "brain endothelial cell", "cerebrovascular", "gene therapy", "high risk", "in vivo", "inhibitor", "macromolecule", "mouse model", "neuroinflammation", "neurotoxic", "novel", "novel strategies", "post SARS-CoV-2 infection", "post-pandemic", "prevent", "programs", "promote resilience", "respiratory", "response", "small molecule", "therapeutic target", "transcriptome sequencing", "vascular cognitive impairment and dementia", "vascular stress" ], "approved": true } }, { "type": "Grant", "id": "15771", "attributes": { "award_id": "1R01AI185685-01A1", "title": "Multi Parametric Total-Body Imaging of Immune Activation in Post Acute Sequelae of SARS-CoV-2 (PASC)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32843, "first_name": "JOSEPH J", "last_name": "BREEN", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-01", "end_date": "2029-07-31", "award_amount": 808672, "principal_investigator": { "id": 32844, "first_name": "Negar", "last_name": "Omidvari", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2639, "ror": "", "name": "UNIVERSITY OF CALIFORNIA AT DAVIS", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Post-acute sequelae of SARS-CoV-2 infection (PASC) is a persisting health challenge characterized by a range of symptoms affecting multiple organ systems, which continues to impact approximately 10% of COVID-19 survivors. Multiple, potentially overlapping, mechanisms have been identified that may play a role in PASC. However, with no effective preventative measures or treatments, there is a critical unmet need for understanding the pathophysiology of PASC; as previous studies, often limited by focus on peripheral blood biomarkers only or confined to single organ systems, have not sufficiently and quantitatively investigated the multisystemic and immune-related complexities of this condition in non-blood tissue. The long-term objective of this project is to bridge this knowledge gap by providing insight into the immune and systemic manifestations of PASC, through the innovative use of total-body dynamic positron emission tomography (PET) with the 18F-AraG radiotracer, which particularly offers selectivity towards activated T cells. To achieve this, we will use the dynamic PET images obtained from a high-sensitivity total-body PET scanner to develop, optimize, and validate a kinetic model for 18F-AraG in different anatomical sites and tissue types for multi parametric quantification of uptake. We expect that this will not only improve the quantification accuracy compared to standard static imaging, but also can shed light on the underlying mechanisms of uptake. The multi parametric imaging will be firstly used to identify sites of immunological perturbation in PASC patients, offering a total-body view of tissue-level manifestations of PASC. For this, we will compare the kinetic parameters of different tissues between symptomatic PASC participants and a control group consisting of individuals with a complete COVID-19 recovery. Second, we will integrate the multiparametric imaging data with peripheral blood assays, aiming to assess the correlations between certain 18F-AraG kinetic parameters and biomarkers of inflammation, immune dysregulation, and endothelial dysfunction in peripheral blood. Particularly, to identify vascular alterations in tissue and their association with endothelial markers in blood, we will use vascular permeability modeling to estimate the blood flow in different tissues from the early frames of the kinetic data. Third, we will employ a longitudinal design to quantify changes in 18F-AraG kinetic parameters and correlate them with evolving PASC symptom profiles over time. We will include two follow-up scans of the PASC participants at 4 months and 8 months after the baseline scans with systematic symptom assessments, focusing on individual patient trajectories. Through this, we expect to establish a direct and meaningful connection between molecular imaging data and clinical manifestations. In summary, the incorporation of cutting-edge imaging technology with quantitative modeling techniques for non- invasive evaluation of total-body immune response, combined with the longitudinal design of the study promises to provide unprecedented insights into this complex condition and would extend well beyond the confines of the PASC condition, offering frameworks and tools that could as well be used for other post-viral conditions.", "keywords": [ "2019-nCoV", "Affect", "Anatomy", "Autoimmunity", "Autopsy", "Biological Assay", "Biological Markers", "Biopsy", "Blood", "Blood Vessels", "Blood coagulation", "Blood flow", "Blood specimen", "Body System", "COVID-19", "COVID-19 patient", "COVID-19 survivors", "Cardiovascular system", "Cells", "Clinical", "Complex", "Control Groups", "Controlled Study", "Data", "Endocrine", "Endothelium", "Evaluation", "Functional disorder", "Guanine", "Health", "Image", "Imaging Techniques", "Imaging technology", "Immune", "Immune response", "Immunologic Markers", "Immunologics", "Individual", "Inflammation", "Kinetics", "Knowledge", "Latent virus infection phase", "Link", "Long COVID", "Masks", "Measures", "Modeling", "Monitor", "Organ", "Outcome", "Participant", "Patients", "Persons", "Phenotype", "Positron-Emission Tomography", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Preventive measure", "Preventive treatment", "Quality of life", "Questionnaires", "Radiopharmaceuticals", "Recovery", "Regional Anatomy", "SARS-CoV-2 infection history", "Sampling", "Scanning", "Site", "Symptoms", "System", "T-Cell Activation", "Techniques", "Technology", "Time", "Tissues", "Tracer", "Vascular Permeabilities", "Viral", "Virus Diseases", "acute COVID-19", "blood-based biomarker", "endothelial dysfunction", "follow-up", "forging", "gastrointestinal", "health care burden", "healthy volunteer", "imaging agent", "imaging approach", "imaging biomarker", "imaging study", "immune activation", "immune imaging", "improved", "individual patient", "innovation", "insight", "kinetic model", "longitudinal design", "molecular imaging", "multiparametric imaging", "neuropsychiatry", "pandemic response", "peripheral blood", "personalized diagnostics", "personalized intervention", "personalized medicine", "pre-pandemic", "predictive marker", "pulmonary", "quantitative imaging", "radiotracer", "reactivation from latency", "sample collection", "tool", "treatment strategy", "uptake" ], "approved": true } }, { "type": "Grant", "id": "15779", "attributes": { "award_id": "1R01AI197146-01", "title": "SCH: A structural causal framework for adaptive experiments", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 32567, "first_name": "MEGHAN ANN", "last_name": "HARTWICK", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-06", "end_date": "2029-07-31", "award_amount": 299422, "principal_investigator": { "id": 32855, "first_name": "Ivan", "last_name": "Diaz", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 32856, "first_name": "Michele", "last_name": "Santacatterina", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 2643, "ror": "", "name": "NEW YORK UNIVERSITY SCHOOL OF MEDICINE", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Adaptive randomized clinical trials are critical in infectious disease research, offering flexibility to adjust sample sizes, introduce new interventions, discontinue ineffective treatments, and target specific subgroups to enhance treatment efficacy. This adaptability is particularly valuable in rapidly evolving public health crises, such as the development of treatments for emerging infectious diseases like COVID-19. However, adaptive trials present significant challenges, including unclear inferential targets, statistical biases from temporal and spatial variability, complexities in handling dynamic data structures, and an increased risk of false-positive findings. These concerns are reflected in recent FDA guidance on estimands, which emphasizes the need for clearly defined inferential targets, and on adaptive designs, which acknowledges that statistical bias in adaptive trials remains an understudied issue. Despite these recognized challenges, current research lacks a principled framework for structurally representing and unbiasedly estimating causal effects in adaptive trials. This project will develop a structural causal framework for adaptive trials, leveraging modern causal inference and statistical techniques alongside secondary data from the Adaptive COVID-19 Treatment Trial (ACTT)—an adaptive trial evaluating novel therapeutics in hospitalized COVID-19 patients—to enable transparent, efficient, and statistically unbiased estimation of causal effects. To achieve this, we propose the following specific aims: Aim 1: Develop a structural causal approach that deals with temporal variability. Aim 2: Extend our framework to handle spatial variability. Aim 3: Expand our framework to handle complex data structures, including failure-time and missing data, while dealing with false-positive results. Our project aligns with NIAID’s mission by advancing key methodologies for infectious disease clinical trials, particularly in adaptive designs for pandemic response, emerging pathogens, and the development of antiviral treatments. While our primary focus is on infectious disease trials, our methods have broader applicability to other disease areas, such as schizophrenia. We show this by also leveraging secondary data from schizophrenia studies, including the DECIFER trial, the RAISE study, and the EPINET study. RELEVANCE (See instructions): This research aims to improve how adaptive clinical trials are designed and analyzed. By developing methods that address key challenges in adaptive trials, our work will help ensure more accurate and reliable results, ultimately leading to better treatments and public health responses to emerging infectious diseases.", "keywords": [ "Address", "Area", "COVID-19", "COVID-19 patient", "COVID-19 treatment", "Clinical Trials", "Clinical Trials Design", "Communicable Diseases", "Data", "Disease", "Emerging Communicable Diseases", "Ensure", "Failure", "Hospitalization", "Infectious Diseases Research", "Instruction", "Intervention", "Methodology", "Methods", "Mission", "Modernization", "National Institute of Allergy and Infectious Disease", "Public Health", "Reliability of Results", "Research", "Risk", "Sample Size", "Schizophrenia", "Statistical Bias", "Structure", "Subgroup", "Techniques", "Time", "Treatment Efficacy", "Work", "antiviral drug development", "complex data", "design", "emerging pathogen", "experimental study", "flexibility", "improved", "ineffective therapies", "novel therapeutics", "pandemic response", "randomized clinical trials", "response", "spatiotemporal", "therapy development", "treatment trial" ], "approved": true } }, { "type": "Grant", "id": "15780", "attributes": { "award_id": "1R01CA293884-01A1", "title": "The impact of dyadic processes on smoking and cigarette craving: An experimental investigation of romantic partners and smoking friends", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 32857, "first_name": "REBECCA", "last_name": "FERRER", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-07", "end_date": "2029-07-31", "award_amount": 2202321, "principal_investigator": { "id": 32858, "first_name": "Amanda", "last_name": "Forest", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 32859, "first_name": "MICHAEL Andrew", "last_name": "SAYETTE", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 2644, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Smoking is the leading preventable cause of cancer and mortality in the US, with Covid hitting smokers especially hard. Quitting is difficult (and smoking increased during Covid), yet interventions yield only mixed success. Smokers often smoke and crave cigarettes in social settings. Public health research emphasizes social factors in smoking, and clinical studies point to the need to better understand disrupted relationship dynamics when a romantic partner or friend quits. Thus, it is striking that nearly all lab research (testing causal relations) on smoking and craving tests smokers in isolation. This neglect of social factors extends to quitting practices. Even on the most respected websites, the “social” advice for quitting offers fairly simplistic and incomplete tips that fail to consider subtle yet powerful challenges that quitting may create for smoking friends and romantic partners. Further, there is no evidence regarding how social factors exacerbate the altered smoking-related decision-making that accompanies craving, thus raising the likelihood of smoking. To develop a comprehensive understanding of the factors and processes that maintain smoking and increase relapse risk, basic experimental research that integrates social processes into existing paradigms focusing on pharmacologic and (individual) psychological aspects of addiction is needed. This basic experimental study with humans (BESH) application addresses targeted NCI Behavioral Research Program priorities focused on leveraging research on dyadic processes to examine health-related behaviors such as smoking cessation. Integrating theory and research derived from three disciplines rarely applied to smoking (experimental social psychology with a focus on dyadic processes, affective science, cognition), the project will offer a multimodal analysis of craving and smoking in two social contexts relevant to smoking (friendships, romantic couples). This project will use innovative measures of affect (e.g., an urge pressure dynamometer, speech volume, Facial Action Coding System) and decision-making to test theoretically-derived processes (e.g., shared reality, motivated reasoning, emotional contagion) that may help explain the challenges linked to quitting when rewarding social aspects of smoking are lost. The project will elucidate why some smokers may struggle managing relationships when quitting, and why social interventions may be most useful for a subset of smokers. In both a friends study and a couples study, abstinent daily and nondaily smokers will be recruited. The friends study will test the impact of a friend’s presence on cue-elicited craving, with a focus on shared craving states, and the couples study will target effects of mutual smoking versus unilateral smoking on critical social interactions and relationship perceptions thought to raise obstacles to quitting. This project will test important social-cognitive and socio- emotional mechanisms underlying craving and smoking that may identify hidden social motives for smoking that must be integrated into biopsychosocial smoking treatment. Regardless of outcome, this work will provide valuable data on emotional and cognitive processes experienced in social settings during craving and smoking.", "keywords": [ "Acoustics", "Address", "Affect", "Affective", "American", "Behavioral Research", "Cancer Etiology", "Cessation of life", "Cigarette", "Clinical", "Clinical Research", "Code", "Cognition", "Cognitive", "Couples", "Cues", "Data", "Decision Making", "Discipline", "Disclosure", "Electronic cigarette", "Emotional", "Emotions", "Event", "Face", "Friends", "Friendships", "Future", "Goals", "Health", "Health behavior", "Human", "Individual", "Intervention", "Investigation", "Language", "Link", "Malignant Neoplasms", "Measures", "Methodology", "Methods", "Modeling", "Monitor", "Nicotine", "Nicotine Dependence", "Outcome", "Patient Self-Report", "Perception", "Persons", "Pharmaceutical Preparations", "Play", "Preventable cancer cause", "Process", "Public Health", "Reporting", "Research", "Rewards", "Role", "Science", "Smiling", "Smoke", "Smoker", "Smoking", "Smoking treatment", "Social Environment", "Social Interaction", "Social Processes", "Social Psychology", "Speech", "Subgroup", "Testing", "Tobacco", "Treatment Efficacy", "Work", "addiction", "biopsychosocial", "cigarette craving", "cigarette smoking", "cognitive process", "contagion", "craving", "experience", "experimental study", "heuristics", "innovation", "insight", "member", "mortality", "multimodality", "neglect", "novel", "pharmacologic", "premature", "pressure", "prevent", "programs", "psychologic", "public health research", "recruit", "relapse risk", "smoking cessation", "smoking cue", "social", "social factors", "social interventions", "social relationships", "success", "theories", "web site" ], "approved": true } }, { "type": "Grant", "id": "15817", "attributes": { "award_id": "1R01LM014760-01", "title": "Virtual World-based Cardiac Rehabilitation to Promote Data-Powered Cardiovascular Health Among Cardiac Patients: A Multicenter Randomized Clinical Trial", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Library of Medicine (NLM)" ], "program_reference_codes": [], "program_officials": [ { "id": 44224, "first_name": "GOUTHAM", "last_name": "REDDY", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-09-09", "end_date": "2029-07-31", "award_amount": 390852, "principal_investigator": { "id": 44225, "first_name": "LaPrincess C", "last_name": "Brewer", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1426, "ror": "", "name": "MAYO CLINIC ROCHESTER", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true }, "abstract": "Despite well-established benefits of reduced mortality and improved quality of life, <25% of eligible patients participate in cardiac rehabilitation (CR). Disparities in CR participation are particularly worse among patients most affected by cardiovascular (CV) disease including those of lower socioeconomic status and those living in rural and dense urban areas. Participation barriers include inflexible CR hours and considerable distances to CR centers. In the post-COVID-19 pandemic era, novel CR delivery methods to mitigate barriers to care are crucial. Data-driven telehealth models using virtual technologies have emerged to expand CR access through home-based delivery. One such modality, virtual worlds (VWs), are 3-D, immersive computer-based environments allowing users to interact via online personas (avatars), simulate in-person experiences, and social network. VWs are applied for physical rehabilitation, health education, and chronic disease management and could address CR participation barriers. Our major project goal is to use a Hybrid Type 1 implementation trial design to rigorously test the efficacy of a behavioral theory-informed, 12-week, VW-based CR (VWCR) intervention compared to center-based CR (CBCR) for improving CV health and CR participation among cardiac patients. CV health will be measured by the American Heart Association Life’s Essential 8 (LE8) composite score, an evidence-based metric of 8 health-promoting behaviors/clinical factors (e.g., diet, blood pressure) that improves CV outcomes. We will conduct a multiphase, multicenter, 2-arm, randomized controlled non-inferiority trial with 150 adult cardiac patients. We hypothesize that patients randomized to our patient-centric VWCR intervention will have noninferior CV health profiles and higher adherence rates than those randomized to CBCR. This R01 proposal aligns with the NLM’s focus on next-generation technologies to “reach more people in more ways through enhanced dissemination and engagement.” Building on our patient informed VWCR preliminary work, we propose 2 aims. Aim 1 will determine the effect of VWCR on CV health among cardiac patients compared to CBCR. Primary outcome is the LE8 score. Aim 2 will determine whether patients randomized to VWCR will have improved participation in and adherence to CR compared to those in CBCR. Primary outcome is adherence (attendance of ≥70% of sessions prescribed). We will use mixed methods to assess adherence and sustainability/scalability potential. Secondary outcomes include major adverse CV events, psychosocial measures (quality of life, self-efficacy, self-regulation, social support), cost effectiveness and implementation outcomes according to the RE-AIM framework. A Patient/Community/Stakeholder Advisory Board will provide input for all activities. Our innovative, reproducible VWCR intervention integrates theory-informed and empirically supported components to influence the LE8. If successful, our results can pave the way for scalable, broad implementation of VWCR to increase CR accessibility and improve CV health outcomes among cardiac patients.", "keywords": [ "3-Dimensional", "Active Learning", "Address", "Adherence", "Adult", "Affect", "Age", "American Heart Association", "Behavior", "Behavioral", "Biometry", "Blood Pressure", "COVID-19 pandemic", "Cardiac", "Cardiac rehabilitation", "Cardiovascular Diseases", "Cardiovascular system", "Chronic Disease", "Clinical", "Communities", "Computers", "Data", "Destinations", "Development", "Diet", "Discipline of Nursing", "Disease Management", "Disparity", "Education", "Elements", "Eligibility Determination", "Environment", "Event", "Exercise", "Exercise Physiology", "Feasibility Studies", "Fitness Centers", "Geographic Locations", "Goals", "Health Care", "Health Care Costs", "Health Policy", "Health Professional", "Health Promotion", "Health behavior", "Health education", "Home", "Hour", "Hybrids", "Informal Social Control", "Insurance Coverage", "Intervention", "Life", "Lipids", "Measures", "Methods", "Modality", "Modeling", "Outcome", "Patient Participation", "Patient-Focused Outcomes", "Patients", "Persons", "Phase", "Physical Rehabilitation", "Physical activity", "Pilot Projects", "Population", "Prevention program", "Quality of life", "Randomized", "Reach Effectiveness Adoption Implementation and Maintenance", "Rehabilitation Centers", "Reproducibility", "Research", "Restaurants", "Rural", "Self Determination", "Self Direction", "Self Efficacy", "Social Network", "Social support", "Support Groups", "Technology", "Telemedicine", "Testing", "Translating", "Transportation", "Travel", "United States National Library of Medicine", "Weight", "Work", "adherence rate", "arm", "barrier to care", "cardiovascular disorder prevention", "cardiovascular health", "cardiovascular risk factor", "clinical practice", "clinically relevant", "comparison intervention", "cost", "cost comparison", "cost outcomes", "demographics", "design", "digital health", "effectiveness outcome", "efficacy testing", "evidence base", "exercise intensity", "exercise rehabilitation", "experience", "flexibility", "hands-on learning", "healthy lifestyle", "hospital readmission", "implementation determinants", "implementation outcomes", "implementation trial", "improved", "innovation", "low socioeconomic status", "mortality", "next generation", "novel", "pandemic disease", "patient oriented", "patient population", "post-COVID-19", "primary outcome", "programs", "prototype", "psychosocial", "quality of life i" ], "approved": true } }, { "type": "Grant", "id": "15167", "attributes": { "award_id": "1K01HL165086-01A1", "title": "LeveRaging Community Engagement to SusTAIN NCD InTegrated Care Models (RETAIN-IT)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 31750, "first_name": "Keith A", "last_name": "Mintzer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-01", "end_date": "2029-08-31", "award_amount": 162820, "principal_investigator": { "id": 31751, "first_name": "Angela", "last_name": "Aifah", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 832, "ror": "", "name": "NEW YORK UNIVERSITY SCHOOL OF MEDICINE", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "The increased life expectancy of people living with HIV/AIDS (PLWH) and the associated burden of non- communicable diseases (NCDs) in PLWH has prompted an urgent need for effective community engaged strategies that engage care PLWH with comorbid NCDs in clinical treatment. Current integrated models of care lack a focus on community engagement as a strategy to refer impacted individuals to clinical treatment – an integral aspect of translating evidence-based practices (EBPs) in LMICs. More specifically, despite the use of community clinical linkages as an effective strategy to link impacted individuals to clinical treatment for complex health conditions (such as opioid use disorder and emerging infections like the COVID-19 pandemic), its use for NCD prevention among PLWH and comorbid hypertension in low- and middle-income countries (LMICs) is suboptimal. In order to sustain the public health gains made in the treatment of HIV, community clinical linkages must be prioritized as a key component of HIV/NCD integrated care models in LMICs. Guided by the Community- Based System Dynamics (CBSD) and Human-Centered Design (participatory approaches that involve participants in developing solutions to complex system challenges), this K01, “LeveRaging Community Engagement to SusTAIN NCD InTegrated Care Models (RETAIN-IT)”, leverages the infrastructure of a community-based organization (Network of People Living with HIV in Nigeria (NEPWHAN)) to co-develop a community-clinical linkage (CCL) model that will facilitate the referral of PLWH to primary healthcare centers for hypertension treatment. The research aims of this proposal are to: 1) identify and map the multi-level barriers and facilitators of developing a community-clinical linkage model for care of PLWH and comorbid hypertension in Akwa Ibom, Nigeria; 2) co-develop with NEPWHAN, a culturally tailored, community led strategy for linking PLWH with comorbid hypertension to primary health centers for management of hypertension; and 3) assess the acceptability, appropriateness, and feasibility of the community-led strategy using a pre-post pilot study design. To accomplish these research aims and prepare for a larger study, the applicant will receive training in: 1) systems science theory and methods, including community-based system dynamics; 2) partnership building with community partners; and 3) in using community clinical linkage models as an implementation strategy for advancing evidence-based practices for integrated models of care in PLWH and comorbid NCDs under the direction of Drs. Gbenga Ogedegbe, Antoinette Schoenthaler, Nadia Islam, Brita Roy, and Dike Ojji. Findings from the proposed research will advance research on the role of community clinical linkages in sustaining integrated NCD models of care in LMICs and directly aligns with NHLBI’s strategic goal to advance translational research by facilitating innovation and accelerating research translation.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15173", "attributes": { "award_id": "1K23HL171862-01A1", "title": "Myeloid-derived suppressor cells modulate disease severity in children with viral lower respiratory tract infections", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 31460, "first_name": "BEENA G", "last_name": "Sood", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-01", "end_date": "2029-08-31", "award_amount": 180199, "principal_investigator": { "id": 31758, "first_name": "Katherine", "last_name": "Bline", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 879, "ror": "", "name": "RESEARCH INST NATIONWIDE CHILDREN'S HOSP", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "Severe lower respiratory tract infection (LRTI) due to viral pathogens remains one of the most common causes of death for young children worldwide. Current management of patients with viral-induced LRTI focuses on supportive care, but outcomes may be improved by augmenting the host immune response to fight the virus and regain immune homeostasis. A growing body of literature suggests that children with severe viral LRTI have an impaired adaptive immune response, specifically decreased T cell proliferation and cytokine production. Myeloid- derived suppressor cells (MDSC) are a heterogeneous cell population that expand during inflammatory conditions and potently inhibit T cell proliferation and function. MDSC have been extensively studied in adult oncologic populations where clinical trials show promising results of improved outcomes by inhibiting MDSC as part of chemotherapy and anti-tumor vaccine treatment regimens. Our group has identified significant increases in the frequency of MDSC populations in children with septic shock and COVID-19 and demonstrated associations between increased percentages of MDSC and worse clinical outcomes. However, it is unknown what role MDSC play in children with viral-induced severe LRTI. The overall goal of this proposal is to identify MDSC as contributors to the immune response in children with viral LRTI and identify mechanistic pathways as potential therapeutic targets for future investigations. Our central hypothesis is that increased frequency of MDSC will be associated with worse clinical outcomes and decreased numbers of CD4+ and CD8+ T cells in children with viral LRTI, and that pediatric MDSC-induced T cell suppression is reversible through inhibition of the PD-1 pathway. The proposed experiments will involve blood sampling of children with PCR-confirmed viral LRTI to characterize the dynamics of MDSC and lymphocyte populations during hospitalization. We will also use our in vitro model of MDSC induced from pediatric peripheral blood mononuclear cells and select patient samples to establish the PD-1 pathway as an important mechanism of MDSC-mediated inhibition of T cell proliferation and cytokine production in children. This career development award will generate the necessary data to inform the design of future studies of the pediatric immune response in severe lower respiratory tract infections and will equip me with the necessary tools to achieve independence as a patient- oriented clinician-scientist.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15175", "attributes": { "award_id": "1U01IP001266-01", "title": "RFA-IP-24-046: Nationwide Cohort of Blood Donors to Estimate Burden of Respiratory Viruses and Immunologic Response", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Immunization and Respiratory Diseases (NCIRD)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2024-09-01", "end_date": "2029-08-31", "award_amount": 4500000, "principal_investigator": { "id": 23549, "first_name": "MICHAEL Paul", "last_name": "BUSCH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1617, "ror": "", "name": "VITALANT", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 2514, "ror": "", "name": "VITALANT", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The program consortium, led by Vitalant Research Institute (VRI), is comprised of the American Red Cross (ARC) and Vitalant (VTL), the two largest US Blood Collection Organizations (BCOs); Creative Testing Solutions (CTS), the nation’s largest blood and plasma donor testing laboratory network; and Westat, one of the premier research, data collection, survey, and statistical analysis organizations in the US. This team has capitalized on our collective experience acquired through successful completion of past and ongoing national studies addressing blood donor epidemiology and recipient safety using unique access to blood donors’ serial donation-derived samples, large-scale high throughput blood screening, BCO donor-donation databases, survey data, and analytics capacity. We will maintain a longitudinal cohort of at least 30,000 donors who are routinely providing blood samples nationally to support quarterly assessment of ~20,000 samples for antibody prevalence, median antibody titers, and incidence of infections. We will maintain and enhance our current nationwide blood donor cohort with sample acquisition, testing, and surveys of ≥2,000 donors in each HHS region to obtain quarterly estimates for a range of respiratory viruses in each region. The following objectives will be accomplished for SARS-CoV-2 using established methodologies, with transition to highly multiplexed, quantitative serology (seroplex) assays to enable additional monitoring of RSV, influenza and other respiratory viruses: estimate population weighted incidence of infections nationally, by HHS region, and within demographic subgroups (e.g., by race/ethnicity, sex, age group) including reinfections using seroconversion or changes in antibody titers in a cohort of repeat blood donors; assess national, regional, and demographic group-specific immunity and risk of infection through tracking antibody titers; monitor antibody dynamics, including waning patterns, and measure the ability to neutralize variants with mutations associated with immune escape; assess demographic and other risk factors for infection in the setting of evolving immunity and the emergence of newly circulating variants; determine antibody thresholds for protection against infections and clinical disease including from new variants; use surveys to document vaccinations, symptoms, severe illness, respiratory virus prevention behaviors, level of exposure to viruses, and attitudes towards respiratory virus vaccines, prophylactic medications, and/or therapeutics; monitor new and persistent symptoms following respiratory virus infections to estimate prevalence and clinical significance of post-acute syndromes, stratified by reported vaccinations and prior infections. This program will expand the established biorepository of nationally representative samples and enhance seroplex assays enabling investigation of novel respiratory viruses, including prevalence, incidence, risk factors, and clinical outcomes.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15176", "attributes": { "award_id": "1K01AI182501-01", "title": "Applying a Targeted Machine Learning and Causal Inference Approach to Analyzing Long-Term Sequelae of COVID-19 Infection Through the National COVID Cohort Collaborative.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6125, "first_name": "Timothy A.", "last_name": "Gondre-Lewis", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-04", "end_date": "2029-08-31", "award_amount": 134923, "principal_investigator": { "id": 31760, "first_name": "Zachary", "last_name": "Butzin-Dozier", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1079, "ror": "", "name": "UNIVERSITY OF CALIFORNIA BERKELEY", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "/ ABSTRACT Candidate: I am an epidemiologist in the Division of Biostatistics at the University of California, Berkeley School of Public Health, and I completed my Ph.D. in Epidemiology in August 2022 at UC Berkeley. Since my graduation, I have worked with the Center for Targeted Machine Learning and Causal Inference (CTML) to apply cutting-edge biostatistical and causal inference methods to pressing COVID-19 research questions using data from the National COVID Cohort Collaborative (N3C). I led a group of CTML epidemiologists and biostatisticians in the NIH Long COVID Computational Challenge (L3C) competition, where we were honored with third place for our ensemble machine learning model that accurately predicted the risk of Long COVID diagnosis based on individual electronic health record (EHR) data in N3C. I aim to become a leader in the application of innovative biostatistical, causal inference, and machine learning methods to impactful research questions related to infectious disease epidemiology. Environment: In order to attain my career goals, my training and mentorship plan will focus on recent advances in biostatistics, causal inference, and data science methods (Targeted Machine Learning) as well as immunology and infectious disease epidemiology. I have assembled an interdisciplinary team of expert biostatisticians, epidemiologists, and clinicians who will support my training. Alan Hubbard (primary mentor) and Mark van der Laan (co-mentor) will provide expert guidance and mentorship on biostatistics, data science, and causal inference. Rena Patel (co-mentor) and Jack Colford (scientific advisor) will provide mentorship and guidance in infectious disease epidemiology and immunology. Research: Researchers and clinicians have made enormous progress in understanding, preventing, and treating acute COVID-19 infection, but there is considerable uncertainty regarding the factors associated with long-term sequelae of COVID-19 infection. Although vaccination is a key strategy for COVID-19 epidemic control, little is known regarding the role of COVID-19 vaccination timing relative to COVID-19 infection (i.e., up-to-date vaccinations and boosters) in preventing long-term sequelae of infection, and the lack of objective Long COVID biomarkers hampers our ability to evaluate, prevent, and treat Long COVID. In Aim 1, I will evaluate the relationship between vaccination timing and Long COVID diagnosis in order to determine an optimized vaccination schedule to minimize Long COVID. In Aim 2, I will assess the relationship between COVID-19 vaccination timing and individual long-term sequelae of COVID-19 infection. In Aim 3, I will assess mediation of the relationship between acute COVID-19 infection and Long COVID via interleukin 6 (IL-6) to evaluate a biological mechanism of interest. I will apply Targeted Machine Learning methods to achieve these aims, which will prepare me for an R01-level application to apply these methods to research questions in infectious disease epidemiology.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15192", "attributes": { "award_id": "1R01HL172859-01", "title": "Mitochondrial metabolism controls alveolar epithelial cell fate", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 26329, "first_name": "SIDDHARTH KAUP", "last_name": "Shenoy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-01", "end_date": "2029-08-31", "award_amount": 616000, "principal_investigator": { "id": 31773, "first_name": "Seunghye", "last_name": "Han", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 924, "ror": "", "name": "NORTHWESTERN UNIVERSITY AT CHICAGO", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "Patients with severe pandemic SARS-CoV-2 pneumonia suffered damage of alveolar epithelial cells due to direct viral injury, subsequent immune response, and secondary bacterial pneumonia, which presents clinically as the acute respiratory distress syndrome (ARDS). Despite a similar severity of ARDS, some patients recover their lung function without sequelae, while others develop persistent respiratory symptoms and radiographic abnormalities, or progressive lung fibrosis resulting in death or requiring lung transplantation. The mechanisms driving the heterogeneous outcomes remain elusive. Mitochondrial dysfunction and metabolic changes are commonly observed in patients with severe pneumonia/ARDS and in patients with lung fibrosis but whether this dysfunction is causally related to failed epithelial repair after injury is not known. We focus on an intermediate epithelial cell population expressing genes characteristic of both alveolar epithelial type 2 (AT2) and type 1 (AT1) cells. These “transitional cells” are expanded during postnatal development and in several models of lung injury and fibrosis, and human fibrotic lungs. In our published and preliminary studies, we observed that mitochondrial complex I (MCI)-dependent NAD+ regeneration, independent of ATP synthesis, is necessary for postnatal alveologenesis. Rather than inducing a metabolic crisis and cell death, lung epithelial- specific deletion of NDUFS2, an essential MCI subunit protein, prevented AT2-to-AT1 differentiation resulting in a dramatic expansion of transitional cells and subsequent death of the animal from respiratory failure. Transitional cells lacking MCI function demonstrate activation of the integrated stress response (ISR) and a small molecule inhibitor of the ISR rescued the lethality of the knockout mice. I also observed that loss of NDUFS2 in adult AT2 cells leads to the spontaneous development of lung fibrosis and death of the animal from respiratory failure within several months, highlighting the potential importance of this pathway in lung fibrosis. Collectively, we hypothesize that the loss of MCI function increases the mitochondrial NADH/NAD+ ratio through a pathway that requires OMA1, DELE1, and HRI to activate the ISR and enhance ATF4-mediated transcription, precluding normal alveolar epithelial differentiation. I will test this hypothesis in the following two aims: Aim 1: To determine whether an increased mitochondrial NADH/NAD+ ratio and DELE1 are necessary for ISR activation that precludes AT2 to AT1 differentiation in the absence of mitochondrial complex I. Aim 2: To determine whether epithelial ATF4 activation is necessary and/or sufficient for impaired AT2 to AT1 differentiation. We propose causal experiments using sophisticated genetic murine models to link mitochondrial metabolism, activation of the ISR, and failed epithelial differentiation to the development of fibrosis. We pair our experiments with samples collected from patients with pulmonary fibrosis at the time of lung transplant, with a goal of credentialling mitochondrial metabolism and the ISR as targets for therapy to prevent and treat lung fibrosis.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1405, "pages": 1419, "count": 14184 } } }